Trial Radar AI
Clinical Trial NCT07361276 (CLEAR-HTN) for Hypertension is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Observational Study That Will Evaluate Treatment Patterns in the Management of Hypertension in Various Scenarios in the Public Primary Care System (CLEAR-HTN) 15,000 Observational

Not yet recruiting
Clinical Trial NCT07361276 (CLEAR-HTN) is an observational study for Hypertension and is currently not yet recruiting. Enrollment is planned to begin on 31 December 2025 and continue until the study accrues 15,000 participants. Led by AstraZeneca, this study is expected to complete by 31 July 2026. The latest data from ClinicalTrials.gov was last updated on 23 January 2026.
Brief Summary
This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).
Detailed Description
This is a retrospective observational cohort study based on secondary use of routinely collected electronic health data. The design was selected to enable population-level characterisation of treatment patterns and clinical inertia (both diagnostic and therapeutic) in the management of hypertension across diverse settings in Brazil's public primary care system (SUS).

The retrospective cohort design allows for effici...

Show More
Official Title

Clinical Landscape of Epidemiology and Assessment of Results in Hypertension

Conditions
Hypertension
Other Study IDs
  • CLEAR-HTN
  • D6970R00015
NCT ID Number
NCT07361276
Start Date (Actual)
2025-12-31
Last Update Posted
2026-01-23
Completion Date (Estimated)
2026-07-31
Enrollment (Estimated)
15,000
Study Type
Observational
Status
Not yet recruiting
Keywords
Blood Pressure, High
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Uncontrolled blood pressure
Proportion of patients with uncontrolled blood pressure (BP ≥ 140/90 mmHg) who did not receive treatment intensification within 3 months of a recorded elevated BP.
through study completion, an average of 1 year
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Antihypertensive treatment
Proportions receiving monotherapy vs. combination therapy; distribution by pharmacologic class.
through study completion, an average of 1 year
Risk stratification
Likelihood of treatment escalation stratified by low/moderate vs. high/very high CV risk.
through study completion, an average of 1 year
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
All
  • Age ≥18 years at the time of Hypertension diagnosis
  • Hypertension diagnosis as retrieved from registered ICD codes or CIAP Codes (primary care codes) in the EMR , OR At least two blood pressure measurements ≥140/90 mmHg during the study period. The blood measurements should be consecutive and obtained within a 30 days period.
  • Continuous follow-up in the same municipality for at least 6 months after index measurement.
  • Availability of structured EMR data including clinical encounters, diagnoses, and prescriptions

- Patients with incomplete data or not traceable in the registration systems
AstraZeneca logoAstraZeneca
Study Central Contact
Contact: AstraZeneca Clinical Study Information Center, 1-877-240-9479, [email protected]
No location data.